^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Boyounuo (bevacizumab biosimilar)

    i
    Other names: LY01008 , LY 01008 , BA1101
    Associations

    News

    Trials
    Company:
    AstraZeneca, Luye Group
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    Associations

    News

    Trials
    3years
    Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    No abstract available
    Clinical • New P2 trial
    |
    ALB (Albumin)
    |
    Avastin (bevacizumab) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Onivyde (nanoliposomal irinotecan) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    over3years
    Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    Clinical • New P2 trial
    |
    ALB (Albumin)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    almost4years
    Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2; N=96; Recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Jun 2020 --> Jun 2021; Trial primary completion date: Jun 2020 --> Jun 2021
    Trial completion date • Trial primary completion date • Clinical
    |
    MSLN (Mesothelin)
    |
    MSLN positive
    |
    Oncomine™ Dx Target Test
    |
    Avastin (bevacizumab) • paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • anetumab ravtansine (BAY 94-9343) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    almost6years
    A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3; N=648; Recruiting; Sponsor: Luye Pharma Group Ltd.
    New P3 trial
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • Boyounuo (bevacizumab biosimilar)